Research Information System
RETINA-VITREUS, vol.30, 2021 (Scopus)
Purpose: In the study we aimed to investigate effect of concomitant epiretinal membrane on results of anti-VEGF treatment in diabetic macular edema. Materials and Methods: In the study we included patients with epiretinal membrane and diabetic macular edema who were followed in the retina unit. Patients received initial loading doses of three injections; followed by 0.5 mg/month ranibizumab injections as needed. In all patients, central macular thickness, optical coherence tomography fi ndings and best-corrected visual acuity were evaluated. RESULTS: The study included 31 eyes of 37 patients (4 patients received bilateral treatment). The mean age of the patients was 62.4±7.4 years. The patients received an average of 3.9 doses of ranibizumab injection. In the study, 12 (38%) of 31 eyes underwent cataract surgery. The mean central macular thickness (CMT) was 429.25±127.41μm at baseline and 324.42±69.74 at the end of treatment (p< 0.01). The mean BCVA (logMAR) was determined as 0.64±0.34 at baseline and 0.50±0.27 after the treatment (p< 0.01). No signifi cant differences were found in the CMT and BCVA between genders (p> 0.05). Conclusion: It was found that anti-VEGF (ranibizumab) treatment provided signifi cant improvement on CMT and BCVA (logMAR) values in cases with diabetic macular edema and epiretinal membrane. Keywords: Epiretinal membrane, macular edema, anti-VEGF